SOL Global Investments Corp.

  • Market Cap: N/A
  • Industry: Miscellaneous
  • ISIN: CA78471G1000
CAD
0.10
-0.02 (-20.0%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

176.52 k

Shareholding (Aug 2025)

FII

0.29%

Held by 1 FIIs

DII

99.71%

Held by 0 DIIs

Promoter

0.00%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard

Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Miscellaneous

stock-summary
Market cap

CAD 5 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.03

stock-summary
Return on Equity

-919.79%

stock-summary
Price to Book

0.71

Revenue and Profits:
Net Sales:
-1 Million
(Quarterly Results - Aug 2025)
Net Profit:
-2 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-80.0%
0%
-80.0%
6 Months
-81.82%
0%
-81.82%
1 Year
-97.47%
0%
-97.47%
2 Years
-89.47%
0%
-89.47%
3 Years
-92.86%
0%
-92.86%
4 Years
-99.38%
0%
-99.38%
5 Years
-99.7%
0%
-99.7%

SOL Global Investments Corp. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
-18.32%
EBIT Growth (5y)
-164.16%
EBIT to Interest (avg)
43.45
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
-2.63
Tax Ratio
33.29%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.29%
ROCE (avg)
26.20%
ROE (avg)
31.15%

Valuation key factors

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.13
EV to EBIT
-0.09
EV to EBITDA
-0.09
EV to Capital Employed
1.15
EV to Sales
-0.20
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-1342.02%
ROE (Latest)
-2552.64%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Bearish
No Trend
OBV
Mildly Bearish
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Aug 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.29%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Aug'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Aug 2025 is -15.38% vs -159.09% in May 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Aug 2025 is 51.61% vs 51.56% in May 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Aug'25",
        "May'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "-1.50",
          "val2": "-1.30",
          "chgp": "-15.38%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.60",
          "val2": "-3.00",
          "chgp": "80.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.80",
          "val2": "0.20",
          "chgp": "300.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1.50",
          "val2": "-3.10",
          "chgp": "51.61%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Nov'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Nov 2024 is 74.16% vs 71.57% in Nov 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Nov 2024 is -51.32% vs 88.52% in Nov 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Nov'24",
        "Nov'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "-2.30",
          "val2": "-8.90",
          "chgp": "74.16%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-42.40",
          "val2": "-41.60",
          "chgp": "-1.92%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "9.00",
          "val2": "7.30",
          "chgp": "23.29%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-0.30",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-51.60",
          "val2": "-34.10",
          "chgp": "-51.32%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Aug'25 - QoQstock-summary

Aug'25
May'25
Change(%)
Net Sales
-1.50
-1.30
-15.38%
Operating Profit (PBDIT) excl Other Income
-0.60
-3.00
80.00%
Interest
0.80
0.20
300.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-1.50
-3.10
51.61%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Aug 2025 is -15.38% vs -159.09% in May 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Aug 2025 is 51.61% vs 51.56% in May 2025

Annual Results Snapshot (Consolidated) - Nov'24stock-summary

Nov'24
Nov'23
Change(%)
Net Sales
-2.30
-8.90
74.16%
Operating Profit (PBDIT) excl Other Income
-42.40
-41.60
-1.92%
Interest
9.00
7.30
23.29%
Exceptional Items
0.00
-0.30
100.00%
Consolidate Net Profit
-51.60
-34.10
-51.32%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Nov 2024 is 74.16% vs 71.57% in Nov 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Nov 2024 is -51.32% vs 88.52% in Nov 2023

stock-summaryCompany CV
About SOL Global Investments Corp. stock-summary
stock-summary
SOL Global Investments Corp.
Miscellaneous
SOL Global Investments Corp, formerly Scythian Biosciences Corp, is a Canada-based investment company. The Company is focused on offering strategic investments and partnerships across cultivation, distribution and retail complement the Company’s research and development (R&D) program with the University of Miami. It is engaged in the process of developing drug therapies. The Company conducts a project regarding development of a cannabinoid-based combination drug therapy for the treatment of concussions and traumatic brain injury. The Company also provides a research in area of treatment of gastro-inflammatory disease.
Company Coordinates stock-summary
Company Details
100 King Street West, Suite 5600 , TORONTO CA : M5X 1C9
stock-summary
Tel: 1 416 3669192
stock-summary
Registrar Details